<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131197">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998477</url>
  </required_header>
  <id_info>
    <org_study_id>V58P15</org_study_id>
    <secondary_id>2013-002080-26</secondary_id>
    <nct_id>NCT01998477</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to &lt;18 Years of Age at Risk for Influenza-Related Complications</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to &lt;18 Years of Age at Risk for Influenza-Related Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety of TIVa or TIVb vaccine in children 3 to &lt; 18
      years of age who are at risk of complications of influenza disease due to underlying
      diseases.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Proportions of subjects reporting solicited adverse events</measure>
    <time_frame>7 days after each vaccination (administered 4 weeks apart)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects reporting unsolicited (serious or predefined) adverse events</measure>
    <time_frame>over a period of approximately 6 to 7 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TIVa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVa</intervention_name>
    <description>Novartis investigational influenza vaccine</description>
    <arm_group_label>TIVa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVb</intervention_name>
    <description>Licensed influenza vaccine</description>
    <arm_group_label>TIVb</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals 3 through 17 years of age with underlying medical conditions that
             indicate an increased risk of complications from influenza infection.

          -  Further eligibility criteria may be discussed by contacting the site(s)

        Exclusion Criteria:

          -  Individuals with any fatal prognosis of an underlying medical condition (&lt;12 month
             life expectancy).

          -  Individuals hospitalized at the time of enrolment.

          -  Individuals with a history of any anaphylaxis, serious vaccine reactions, or
             hypersensitivity to any of the vaccine components.

          -  Further eligibility criteria may be discussed by contacting the site(s)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site 022</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 020</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 021</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 023</name>
      <address>
        <city>Roma</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 031</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 017</name>
      <address>
        <city>Burriana</city>
        <state>Castellon</state>
        <zip>12530</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 016</name>
      <address>
        <city>Castellon de la Plana</city>
        <state>Castellon</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 010</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 015</name>
      <address>
        <city>L'Eliana</city>
        <state>Valencia</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 013</name>
      <address>
        <city>Paiporta</city>
        <state>Valencia</state>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 018</name>
      <address>
        <city>Quart de Poblet</city>
        <state>Valencia</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 030</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 011</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 019</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 012</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 014</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Flu</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
